Probiotics in gastroenterological diseases: Saccharomyces boulardii CNCM I-745 under the spotlight

Probiotics in gastroenterological diseases: Saccharomyces boulardii CNCM I-745 under the spotlight

T.L. Lapina¹, A.A. Khrabrova¹, B.K. Nurgalieva²

¹I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow

²S.D. Asfendiyarov Kazakh National Medical University, Almaty

The basic principle of prescribing probiotics is based on the understanding that while probiotic strains share similar functional properties, their strain-specific characteristics and demonstrated efficacy in addressing particular nosological conditions are crucial. These functions encompass providing colonization resistance, metabolizing dietary substrates, modulating immune responses, and maintaining the integrity of the epithelial barrier. Although different probiotic types and strains exhibit common mechanisms of action, certain probiotic microorganisms possess unique strain-specific features, which offer distinct benefits in medical use. One of the most extensively studied probiotic strains is Saccharomyces boulardii CNCM I-745. This strain exhibits a wide range of beneficial effects, including antagonistic activity against pathogenic and opportunistic microorganisms, such as Clostridium difficile, Candida albicans, and Escherichia coli. It also demonstrates activity against bacterial cytotoxins and enterotoxins, such as C. difficile toxins A and B and cholera toxin. Additionally, S. boulardii CNCM I-745 helps reduce localized inflammation and stimulates the production of short-chain fatty acids. Clinically, S. boulardii CNCM I-745 is indicated for the treatment and prevention of diarrhea of various etiologies. It plays a significant role in preventing antibiotic-associated diarrhea (AAD) and C. difficile-associated disease (CDAD). Furthermore, it enhances the efficacy of Helicobacter pylorieradication therapy while reducing the frequency of related adverse events.

Keywords: probiotic, microbiota, Saccharomyces boulardii CNCM I-745, H. pylori eradication, antibiotic-associated diarrhea, Clostridioides difficile.

For citation: Lapina T.L., Khrabrova A.A., Nurgalieva B.K. Probiotics in gastroenterological diseases: Saccharomyces boulardii CNCM I-745 under the spotlight. RMJ. 2024;11:26–30. DOI: 10.32364/2225-2282-2024-11-5